Even as they eagerly await the upcoming International AIDS Society (IAS) 2019 Conference on HIV Science, Armstrong along with other physicians, scientists, government agencies, and companies are questioning whether the way they've always recruited for clinical trials still serves patients.
"This gets back into what we need to do to end the epidemic," said Carl Dieffenbach, PhD, director of the Division of AIDS at the National Institute of Health's National Institute of Allergy and Infectious Diseases (NIAID). "These questions are critical. We can't just answer them with cohorts from the 80s."
Amid Trump administration proposals regarding the public charge rule, concerned physicians are taking a stand for their immigrant patients — for what they say is a larger good.
Dave A. Chokshi, MD, is an internal medicine doctor at Bellevue Hospital in New York City. It’s a public hospital where, more and more, Chokshi said he’s had to have a new kind of risk-benefit conversation with his predominantly immigrant patient population: Should patients come in to get their blood pressure checked? ...
On Monday, Nina Martinez, a 36-year-old public health expert, became the first living person with HIV in the United States to donate a healthy kidney to another person with HIV. The transplant, according to surgeons who performed the surgeries, was a success.
"HIV is no longer a contraindication for transplant in any way," said Dorry Segev, MD, PhD, of Johns Hopkins University, Baltimore, Maryland, who was the lead surgeon on the procedure this week.
"30 years ago this disease was a death sentence and now someone with HIV can save someone else's life."
SEATTLE — A London man has not had detectable HIV in his system for 18 months, despite not having received treatment during that period.
The remission came after the patient underwent a stem cell transplant. This makes him the second man in history — after the Berlin patient — to have achieved HIV remission after such a transplant. And that has raised questions about whether he might be cured of HIV.
"The Berlin patient was not an anomaly," Ravindra Gupta, MD, from University College London, ...
In 2013, not quite a year after the Food and Drug Administration approved the drug Truvada for HIV prevention, a coalition of 50 experts in HIV and women's health called on U.S. public health agencies to promote the pill and its approach, called pre-exposure prophylaxis, or PrEP, explicitly to women.
Not much happened.
"No one until recently spent time talking about PrEP for women," says Dr. Dawn K. Smith, biomedical interventions implementation officer at the Centers for Disease Control and ...
A battle is brewing in the HIV research world about the best way to prevent HIV transmission. On one side are drugs that target the tissue where exposure to the virus occurs — think a gel or douche. On the other is a whole-body approach. Think a pill or a shot.
At the heart of the debate is a tall, square-jawed scientist in wire-rimmed glasses who still carries himself like a military man: Dr. Craig Hendrix. Hendrix’s career has touched every part of the HIV prevention world. He’s analyzed da...
MEXICO CITY — A whip-thin length of polymer loaded with islatravir, Merck's investigational HIV prevention drug, and implanted into the arm is being investigated as a future option for people who have a hard time taking pills.
The drug — previously referred to at MK-8591 or, for prevention, EFdA — has been a hot topic at HIV conferences in recent years, even though all data presented have come from preclinical nonhuman primate studies.
But in a packed room at the end of a long conference day ...
When people living with HIV walk out of prison, they leave with up to a month's worth of HIV medication in their pockets. What they don't necessarily leave with is access to health care or the services that will keep them healthy in the long term.
That is one of the findings of a study published Tuesday in PLoS Medicine. The study was among the first to follow people with HIV from jail or prison back into the community. What they found was that most people — more than half — fell out of care ...
”AMSTERDAM — "If you're on suppressive ART, you are sexually noninfectious. The risk is zero," said Alison Rodger, MD, from University College London, here at the International AIDS Conference 2018.
Rodger made the statement after presenting results from PARTNER2 that showed zero linked transmissions after nearly 77,000 condomless sex acts between serodiscordant gay couples in which the HIV-positive partner had a suppressed viral load.
The findings were greeted by questions, applause, tears, photos, and a handshake from officials from the National Institutes of Health."
Rigardo Rush spends his days at an Atlanta marketing and branding company thinking about designing products that are easy to use. He is literally a “user-experience” expert.
He spends his nights the way many single people do: socializing with friends, going out, and flirting. Because he is Black, gay, and lives in the South, conversations with friends often turn to what they want and need to protect themselves from HIV.
When people started to show up to Dr. William Cooke's primary care office in Austin, Ind., in 2014 with HIV, Cooke knew it was probably related to the region's opioid epidemic. But what he and the rest of the public health community didn't know was who they were missing or how long the HIV outbreak had been going on.
Now they've got a clearer picture — literally. In visualizations published in the Journal of Infectious Diseases, dots and lines define the constellations of Indiana's HIV outbre...
"Patient-centered care is about providers trying to get into the world of the person who is being taken care of — understanding the disease from their perspective," said Mekbib Gemeda, vice president of diversity and inclusion at the Eastern Virginia Medical School in Norfolk.
As care providers, we do that better when we think about the patient's whole world, ask questions, and assume an approach of "cultural humility" by acknowledging what we don't know about a patient's life and preferences, he explained.
Physician leaders know about the potential dangers of opioid prescriptions for pain, and they’re open to new ideas. But while federal agencies encourage that thinking, they’re not as forthcoming with practical support.
Ann Lindsay, MD, cares for people with complex conditions — people with an average of nine conditions and lots of medications. Often, they have pain. And often, when they first enroll in her clinic, they are on an opioid pain reliever.
So when Lindsay and her husband, Alan Glas...
"There's an ethical obligation to ensure that young, black MSM, including those in observational studies, have access to the best possible HIV prevention package, which includes PrEP," she said. "The South can really benefit from the examples of New York City and San Francisco, and it would be wonderful if we had something similar to what Washington State has, something like an [AIDS Drugs Assistance Program] for PrEP. But you have to have the political will."